Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4037 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

The Medicines Company advances thrombosis therapy

If the trials are successfully completed and cangrelor receives regulatory clearance, the company believes cangrelor will be the first intravenous platelet inhibitor to market that binds directly to

Ganymed anticancer antibodies show high efficacy

Results show Ganymed monoclonal lead antibodies, directed against the company’s GC182 cancer target, are effective against solid human tumors in mouse xenograft models. No toxicity was observed. The

Biosite and Oxford Genome Sciences enter alliance

In particular, these blood-based diagnostics would be designed to enable the early identification of colorectal cancer patients that have relapsed, thus enabling clinicians to select the most appropriate